Our Science
To create a medicine
to treat diseases

of the nervous system
Our Mission
To improve people's quality
of life
through innovative,
sustainable and effective pain relief

About Us » Our Science

Chronic pain ruins quality of life

OUR MISSION is to discover new, safe and effective drugs to make those lives considerably better. We combine smart chemistry and bioscience to discover new medicines to treat diseases of the nervous system.

Our aim has been to develop biased agonists of the delta (δ) opioid receptor (DOR). Unlike the mu (μ) opioid receptor which is the major target of conventional opioid drugs, activating the DOR does not provide good acute analgesia but produces excellent reversal of chronic pain in animal models. DOR agonists have none of the unwanted effects of conventional opioids.

There is currently an international epidemic of opioid overdosing that has led, particularly in the USA, to thousands of deaths and multiple lawsuits against Big Pharma companies. Our compounds are completely different to those conventional mu opioid drugs in terms of mechanism, efficacy and side effect profile.

It was previously thought that activation of particular receptors would have the same effects irrespective of agonist structure but it is now believed that different structures can direct signalling down particular pathways, wanted or unwanted; this is agonist bias.

Current thinking is that preferentially activating G protein signalling vs arrestin protein signalling underpins optimal pharmacology for DOR agonists.

Latest news

View all
December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more
December 22, 2022

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

Read more
October 11, 2022

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read more
September 20, 2022

Good press in SvD

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

Read more

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Awesome 👌